Hydroxychloroquine for genetic lung disease in children
Treatments studied
Part of Lungs & breathing clinical trials.
This early-phase trial studies whether hydroxychloroquine can help children with certain genetic causes of interstitial lung disease (lung scarring/inflammation). It is designed for kids who are currently stable and have not recently taken hydroxychloroquine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is under 18 years old and has a diagnosis of childhood interstitial lung disease (lung scarring/inflammation).
- The lung disease is confirmed to be from a genetic cause, such as genes like SFTPC, SFTPB, ABCA3, NKX2-1, or others listed in the study.
- Your child’s condition is clinically stable, with no major changes to lung or other medicines in the past 4 weeks.
- Your child has not taken hydroxychloroquine (HCQ) in the past 12 weeks.
- No severe current infection flare-ups, and no known allergy to hydroxychloroquine or the tablet ingredients.
- Your child’s kidney function is not too low for the study (based on a GFR test), and they are not in another clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of three medicines (azithromycin, hydroxychloroquine, and prednisone) can help people with scarring or inflammation in the lungs caused by certain genetic changes. It aims to see if these drugs can slow down or improve the lung disease.
This trial tests a new type of eye test (ERG) to detect early damage from hydroxychloroquine, a drug used for conditions like lupus and rheumatoid arthritis. If you take hydroxychloroquine or have never taken it, you might help find better ways to protect your vision.
This study looks at how Plaquenil (hydroxychloroquine) can harm the retina (the eye’s light-sensing layer) and whether genetics affect who gets affected. You may help by sharing medical details and providing an eye-related blood sample so researchers can compare gene patterns to eye findings.
This trial tests hydroxychloroquine to see if it improves symptoms and heart function in people with inflammatory cardiomyopathy (inflammation of the heart muscle). It’s mainly for adults with a specific type of past myocarditis and ongoing heart failure despite standard treatments.
This study looks at whether it is safe for people aged 55 and older with long-standing, stable lupus to stop taking hydroxychloroquine (a medicine that helps control lupus) without their disease flaring up. If you have been taking this medicine for at least 7 years and your lupus has been quiet for a while, you may be able to join.
This trial studies whether hydroxychloroquine can control extrapulmonary sarcoidosis (sarcoidosis outside the lungs) using less steroid treatment. It may help people who need systemic therapy for problems such as eyes, skin, bones, joints, nerves, ENT areas, or high calcium levels from sarcoidosis.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.